|
1
|
Poon D, Anderson BO, Chen LT, Tanaka K,
Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, et al:
Management of hepatocellular carcinoma in Asia: Consensus statement
from the Asian Oncology Summit 2009. Lancet Oncol. 10:1111–1118.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Njei B, Rotman Y, Ditah I and Lim JK:
Emerging trends in hepatocellular carcinoma incidence and
mortality. Hepatology. 61:191–199. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Finn RS, Zhu AX, Farah W, Almasri J, Zaiem
F, Prokop LJ, Murad MH and Mohammed K: Therapies for advanced stage
hepatocellular carcinoma with macrovascular invasion or metastatic
disease: A systematic review and meta-analysis. Hepatology.
67:422–435. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA,
et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N
Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vilgrain V, Pereira H, Assenat E, Guiu B,
Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W,
et al: Efficacy and safety of selective internal radiotherapy with
yttrium-90 resin microspheres compared with sorafenib in locally
advanced and inoperable hepatocellular carcinoma (SARAH): An
open-label randomised controlled phase 3 trial. Lancet Oncol.
18:1624–1636. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kanthaje S, Makol A and Chakraborti A:
Sorafenib response in hepatocellular carcinoma: MicroRNAs as tuning
forks. Hepatol Res. 48:5–14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Axtell MJ, Westholm JO and Lai EC: Vive la
différence: Biogenesis and evolution of microRNAs in plants and
animals. Genome Biol. 12:2212011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu J and Clark AG: Impact of microRNA
regulation on variation in human gene expression. Genome Res.
22:1243–1254. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Berasain C: Hepatocellular carcinoma and
sorafenib: Too many resistance mechanisms? Gut. 62:1674–1675. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gauthier A and Ho M: Role of sorafenib in
the treatment of advanced hepatocellular carcinoma: An update.
Hepatol Res. 43:147–154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Szakács G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu YJ, Zheng B, Wang HY and Chen L: New
knowledge of the mechanisms of sorafenib resistance in liver
cancer. Acta Pharmacol Sin. 38:614–622. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shenouda SK and Alahari SK: MicroRNA
function in cancer: Oncogene or a tumor suppressor? Cancer
Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Davidson-Moncada J, Papavasiliou FN and
Tam W: MicroRNAs of the immune system: Roles in inflammation and
cancer. Ann NY Acad Sci. 1183:183–194. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dong J, Liu Y, Liao W, Liu R, Shi P and
Wang L: miRNA-223 is a potential diagnostic and prognostic marker
for osteosarcoma. J Bone Oncol. 5:74–79. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Streppel MM, Pai S, Campbell NR, Hu C,
Yabuuchi S, Canto MI, Wang JS, Montgomery EA and Maitra A: MicroRNA
223 is upregulated in the multistep progression of Barrett's
esophagus and modulates sensitivity to chemotherapy by targeting
PARP1. Clin Cancer Res. 19:4067–4078. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kurashige J, Watanabe M, Iwatsuki M,
Kinoshita K, Saito S, Hiyoshi Y, Kamohara H, Baba Y, Mimori K and
Baba H: Overexpression of microRNA-223 regulates the ubiquitin
ligase FBXW7 in oesophageal squamous cell carcinoma. Br J Cancer.
106:182–188. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Han J, Zhao F, Zhang J, Zhu H, Ma H, Li X,
Peng L, Sun J and Chen Z: miR-223 reverses the resistance of
EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway. Int J Oncol.
48:1855–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Inuzuka H, Shaik S, Onoyama I, Gao D,
Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, et al:
SCFFBW7 regulates cellular apoptosis by targeting MCL1
for ubiquitylation and destruction. Nature. 471:104–109. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wertz IE, Kusam S, Lam C, Okamoto T,
Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, et al:
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1
and FBW7. Nature. 471:110–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu Y, Sengupta T, Kukreja L and Minella
AC: MicroRNA-223 regulates cyclin E activity by modulating
expression of F-box and WD-40 domain protein 7. J Biol Chem.
285:34439–34446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Minella AC and Clurman BE: Mechanisms of
tumor suppression by the SCFFbw7. Cell Cycle.
4:1356–1359. 2005. View Article : Google Scholar : PubMed/NCBI
|
